Moderna (MRNA)BAILLIE GIFFORD & CO cut its MRNA stake below 5% (4.6%) 4.6%

4.6%

Stake · was 5.3%

18.2M

Shares owned

Stake as of

Jun 30, 2026

Filed

Jul 24, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 1, 2026Company filing · Form 8-K · ResultsReported its results
2. May 1, 2026InsiderDirector sold ~$265K of MRNA shares in the open market
3. May 6, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
4. May 15, 2026InsiderOfficer sold ~$2.58M of MRNA shares in the open market
5. May 21, 2026InsiderDirector sold ~$434K of MRNA shares in the open market
6. Jun 4, 2026InsiderOfficer sold ~$174K of MRNA shares in the open market
7. Jun 15, 2026InsiderOfficer sold ~$2.74M of MRNA shares in the open market

What came next

1. Jul 6, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On July 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed Michael McDonnell to the Board, effective July 8, 2026.”
2. Jul 15, 2026InsiderOfficer sold ~$3.61M of MRNA shares in the open market
3. Jul 24, 20265% stakeBAILLIE GIFFORD & CO reported a passive stake (13G) of 4.6%
4. Jul 31, 2026Company filing · Form 8-K · ResultsReported its results
5. Aug 5, 2026Insider · 1 personInsiders: 4 sales (~$28.7M)
6. Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 13.1%
7. Aug 12, 20265% stakeCapital World Investors reported a passive stake (13G) of 5.6%
8. Aug 19, 2026Congress · 1 personMembers of Congress: 1 purchase, 1 sale
9. Aug 27, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
10. Sep 1, 2026InsiderOfficer sold ~$486K of MRNA shares in the open market
11. Sep 10, 2026Insider · 1 personInsiders: 2 sales (~$4.7M)
12. Sep 14, 2026InsiderOfficer sold ~$5.81M of MRNA shares in the open market
13. Sep 15, 2026InsiderOfficer sold ~$5.88M of MRNA shares in the open market
14. Sep 24, 2026CongressDisclosed partial sale of MRNA — reported range $1,001 - $15,000
15. Sep 30, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 30, 2026, Moderna, Inc. (“Moderna” or the “Company”) announced the appointment of Juan Andres as its Chief Operating Officer (“COO”) effective October 5, 2026.”

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Moderna

For Moderna, OQRO holds 13 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 7 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRNA page.

How this filing works

• Schedule 13D vs 13G

Other disclosures at Moderna

• House Clerk periodic transaction reportOct 7, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 144Sep 15, 2026
• SEC Form 144Sep 14, 2026
• SEC Form 4Sep 14, 2026

Everything OQRO holds on this company is on its MRNA page.